References
- Bowen, S., Tare, N., Inoue, T., Yamasaki, M., Okabe, M., Horii, I., Eliason, J.F., 1999. Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-stimulating factor mutein. Exp Hematol. 27, 425-432. https://doi.org/10.1016/S0301-472X(98)00051-4
- Bronchud, M.H., Potter, M.R., Morgenstern, G., Blasco, M.J., Scarffe, J.H., Thatcher, N., Crowther, D., Souza, L.M., Alton, N.K., Testa, N.G., 1988. In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients. Br. J. Cancer 58, 64-69. https://doi.org/10.1038/bjc.1988.163
- Caliceti, P., 2004. Pharmacokinetics of pegylated interferons: what is misleading? Dig. Liver Dis. 36, S334-339. https://doi.org/10.1016/S1590-8658(04)80002-1
- Crawford. J., 2002. Pegfilgrastim administered once per cycle reduces incidence of chemotherapy-induced neutropenia. Drugs 62, 89-98. https://doi.org/10.2165/00003495-200262001-00007
- Hara, K., Suda, T., Suda, J., Eguchi, M., Ihle, J.N., Nagata, S., Miura, Y., Saito, M., 1988. Bipotential murine hemopoietic cell line (NFS-60) that is responsive to IL-3, GM-CSF, G-CSF, and erythropoietin. Exp. Hematol. 16, 256-261.
- Hill, C.P., Osslund, T.D., Eisenberg, D., 1993. The structure of granulocyte-colony-stimulating factor and its relationship to other growth factors. Proc. Natl. Acad. Sci. U S A. 90, 5167-5171. https://doi.org/10.1073/pnas.90.11.5167
- Jain, A., Jain, S.K., 2008. PEGylation: an approach for drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 25, 403-447. https://doi.org/10.1615/CritRevTherDrugCarrierSyst.v25.i5.10
- Kinstler, O.B., Brems, D.N., Lauren, S.L., Paige, A.G., Hamburger, J.B., Treuheit, M.J., 1996. Characterization and stability of N-terminally PEGylated rhG-CSF. Pharm. Res. 13, 996-1002. https://doi.org/10.1023/A:1016042220817
- Krishnan, S., Chi, E.Y., Webb, J.N., Chang, B.S., Shan, D., Goldenberg, M., Manning, M.C., Randolph, T.W., Carpenter, J.F., 2002. Aggregation of granulocyte colony stimulating factor under physiological conditions: characterization and thermodynamic inhibition. Biochemistry 41, 6422-6431. https://doi.org/10.1021/bi012006m
- Kurfurst, M.M., 1992. Detection and molecular weight determination of polyethylene glycol-modified hirudin by staining after sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Anal Biochem. 200, 244-248. https://doi.org/10.1016/0003-2697(92)90460-O
- Lee, E.N., Kim, Y.M., Lee, H.J., Park, S.W., Jung, H.Y., Lee, J.M., Ahn, Y.H., Kim, J., 2005. Stabilizing peptide fusion for solving the stability and solubility problems of therapeutic proteins. Pharm. Res. 22, 1735-1746 https://doi.org/10.1007/s11095-005-6489-4
- Lee, S.H., Lee, S., Youn, Y.S., Na, D.H., Chae, S.Y., Byun, Y., Lee, K.C., 2005. Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1. Bioconjug Chem. 16, 377-382. https://doi.org/10.1021/bc049735+
- Manavalan, P., Swope, D.L., Withy, R.M., 1992. Sequence and structural relationships in the cytokine family. J. Protein Chem. 11, 321-331. https://doi.org/10.1007/BF01024870
- Molineux. G., 2002. Pegylation: engineering improved pharmaceuticals for enhanced therapy. Cancer Treat. Rev. 28, 13-16. https://doi.org/10.1016/S0305-7372(02)80004-4
- Rajan, R.S., Li, T., Aras, M., Sloey, C., Sutherland, W., Arai, H., Briddell, R., Kinstler, O., Lueras, A.M., Zhang, Y., Yeghnazar, H., Treuheit, M., Brems, D.N., 2006. Modulation of protein aggregation by polyethylene glycol conjugation: GCSF as a case study. Protein Sci. 15, 1063-1075. https://doi.org/10.1110/ps.052004006
- Ribarska, J.T., Jolevska, S.T., Panovska, A.P., Dimitrovska, A., 2008. Studying the formation of aggregates in recombinant human granulocyte-colony stimulating factor (rHuG-CSF), lenograstim, using size-exclusion chromatography and SDSPAGE. Acta Pharm. 58, 199-206. https://doi.org/10.2478/v10007-008-0003-6
- Ryan, S.M., Mantovani, G., Wang, X., Haddleton, D.M., Brayden, D.J., 2008. Advances in PEGylation of important biotech molecules: delivery aspects. Expert Opin. Drug Deliv. 5, 371-383. https://doi.org/10.1517/17425247.5.4.371
- Souza, L.M., Boone, T.C., Gabrilove, J., Lai, P.H., Zsebo, K.M., Murdock, D.C., Chazin, V.R., Bruszewski, J., Lu, H., Chen, K.K., 1986. Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science. 232, 61-65. https://doi.org/10.1126/science.2420009
- Tsuji, J., Hirose, K., Kasahara, E., Naitoh, M., Yamamoto, I., 1985. Studies on antigenicity of the polyethylene glycol (PEG)-modified uricase. Int. J. Immunopharmacol. 7, 725-730. https://doi.org/10.1016/0192-0561(85)90158-4
- Werle, M., Bernkop-Schnurch, A., 2006. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids. 30, 351-367. https://doi.org/10.1007/s00726-005-0289-3
- Yamasaki, M., Asano, M., Okabe, M., Morimoto, M., Yokoo, Y., 1994. Modification of recombinant human granulocyte colony-stimulating factor (rhG-CSF) and its derivative ND 28 with polyethylene glycol. J. Biochem. 115, 814-819. https://doi.org/10.1093/oxfordjournals.jbchem.a124421
- Yang, Z., Wang, J., Lu, Q., Xu, J., Kobayashi, Y., Takakura, T., Takimoto, A., Yoshioka, T., Lian, C., Chen, C., Zhang, D., Zhang, Y., Li, S., Sun, X., Tan, Y., Yagi, S., Frenkel, E.P., Hoffman, R.M., 2004. PEGylation confers greatly extended halflife and attenuated immunogenicity to recombinant methioninase in primates. Cancer Res. 64, 6673-6678. https://doi.org/10.1158/0008-5472.CAN-04-1822
- Yowell, S.L., Blackwell, S., 2002. Novel effects with polyethylene glycol modified pharmaceuticals. Cancer Treat. Rev. 28, 3-6. https://doi.org/10.1016/S0305-7372(02)80002-0